Several East African nations have announced plans to implement Lenacapavir, the biannual injectable HIV prevention drug, shortly after Kenya initiated its rollout.
Kenya became the first East African country to offer Lenacapavir, distributing 21,000 doses at the Riruta Health Centre on February 26.
Following Kenya’s lead, Uganda received its first shipment and plans to begin administration in early March with 19,200 doses donated by the Global Fund, targeting high-burden districts once preparations are complete.
The Tanzania Medicines and Medical Devices Authority approved Lenacapavir late last year, and officials are finalizing training and supply chain logistics before public distribution.
Health workers express optimism about the biannual schedule, which alleviates the daily pill burden for patients. Carol Njomo, an HIV testing counselor at Riruta Health Centre, noted, “Our patients found daily medication tiresome. With this injection, we expect to reduce workloads and better serve those in need.”
In Lesotho, the arrival of Lenacapavir marks a significant advance in combating HIV/AIDS, particularly given the country’s adult HIV prevalence of 17.1%. Deputy Prime Minister Nthomeng Majara emphasized the drug’s importance, stating, “Lenacapavir strengthens our national response to HIV prevention and offers new hope to our communities.”
Kenya and Lesotho join a growing number of African countries where Lenacapavir is both approved and being administered. Eswatini and Zambia began their public rollouts in late 2025, while Zimbabwe has incorporated the drug into its national prevention programs.
South Africa registered Lenacapavir early and plans to launch it publicly in 2026 as part of its essential medicines framework. Regulatory approvals in Botswana, Mozambique, Namibia, Rwanda, and Malawi pave the way for future distribution once supply chains are established.
Kenya’s launch featured Samson Mutua, a 27-year-old from Kawangware, as the first recipient of Lenacapavir, which provides six months of protection with just two injections annually. He described the injectable as a “comfort” compared to daily oral PrEP.
Health Cabinet Secretary Aden Duale praised the rollout, highlighting a significant reduction in new infections over the past decade while emphasizing the ongoing need for prevention, as 1.4 million Kenyans continue to live with HIV. He stated, “This innovation renews our strength in the fight against HIV.”
Lenacapavir’s biannual dosing addresses adherence challenges associated with daily oral PrEP, potentially enhancing retention in prevention programs and alleviating clinic workloads. The World Health Organization and Global Fund support Kenya’s initiative with starter doses, technical guidance, and safety monitoring, with similar assistance extended to Uganda and other nations.
